Aerie Pharmaceuticals (NSDQ:AERI) today launched its once-daily eye-drop product, Rhopressa, which is designed to reduce intraocular pressure in patients with glaucoma or ocular hypertension.
The Durham, N.C.-based company won FDA approval for Rhopressa in December last year, two months before the agency was expected to make a decision.
Get the full story at our sister site, Drug Delivery Business News.
The post Aerie launches glaucoma drug in U.S. appeared first on MassDevice.
from MassDevice https://ift.tt/2HIHdnp
Cap comentari:
Publica un comentari a l'entrada